About GMPKit
Implementation-led operational leadership focused on reducing Cost of Poor Quality (COPQ) in pharmaceutical manufacturing.
GMPKit partners with site leadership to correct structural execution friction inside GMP environments—strengthening ownership, readiness, and governance so performance becomes predictable and results hold.
Why GMPKit Exists
In pharmaceutical manufacturing, instability is almost never a people problem—it is a structural one. Ownership becomes unclear. Readiness erodes. Decisions stall. Deviation backlogs grow. Batch flow becomes unpredictable.
Cost of Poor Quality (COPQ) is the financial expression of this execution friction.
GMPKit was built because we've lived these challenges—not as consultants observing from outside, but as fractional operators embedded inside GMP environments, accountable for results. We've led manufacturing teams through batch failures, deviation backlogs, and inspection pressure. We've stabilized fragile systems, restored governance discipline, and watched talented teams struggle not because they lacked capability, but because structural friction made execution unpredictable.
That frustration became our mission. Traditional consulting delivers recommendations and exits. We stay. We lead implementation with site leadership—strengthening ownership, readiness, and governance so performance becomes predictable and results hold.
Founded in 2023, GMPKit was built to correct those structural conditions—not through advisory reports, but through implementation-led engagements that restore disciplined execution.
It was built on a simple premise: operational recovery requires a structured system—not isolated interventions.
Not ideas. Not slide decks.
A kit—diagnostics, governance systems, execution frameworks, and digital reinforcement—applied with discipline inside GMP environments.
Meet the Founders
GMPKit was founded by two experienced leaders who spent decades supporting pharmaceutical and GMP-regulated operations—not as outside advisors, but as operators accountable for results.
Michael brings over 25 years of pharmaceutical manufacturing experience across biologics, cell therapy, and commercial cGMP operations, including site leadership positions in both Quality and Manufacturing. This dual perspective—rare in the industry—revealed how execution friction compounds when ownership and governance blur between these critical functions.
After leading operational start-ups, scale-ups, and PPQ execution at Bristol Myers Squibb (Juno Therapeutics) and other major biologics manufacturers, Michael founded GMPKit in 2023 to address a persistent challenge: sites struggling with execution friction don't need more advice—they need structured implementation that restores ownership, readiness, and governance discipline. His mission is to help manufacturing leaders turn operational instability into predictable performance using COPQ as the unifying lens.
Areas of Expertise
Paul brings over 24 years of experience spanning information technology, automation, operational technology (OT), digital transformation, and regulated manufacturing. At Genentech, he led automation systems (OT) operations supporting research, manufacturing, and distribution, with responsibility for system reliability, inspection readiness, and business continuity. Throughout his career, he has specialized in strengthening fragile operating environments by building sustainable systems of ownership, governance, and execution.
After seeing the same operational challenges repeat across regulated manufacturing, Paul co-founded GMPKit to help life sciences manufacturers build reliable operational execution. His work focuses on strengthening governance, digital enablement, and operating models that continue to perform under regulatory scrutiny, business continuity challenges, and real-world operational demands.
Areas of Expertise
How We Think About Manufacturing
We believe operational stability is structural—not driven by heroics, not sustained by urgency, not fixed through isolated projects. Stability emerges when four conditions are met.
Ownership is Explicit
Every process, deviation, and decision has a named owner. Ambiguity is the root of most execution failure.
Readiness is Disciplined
Batch readiness, line clearance, and personnel qualification are treated as structural inputs—not last-minute checks.
Governance Accelerates Decisions
Governance systems should close loops and move work forward—not create bottlenecks that stall execution.
Execution Follows Sequence
Disciplined sequencing of work prevents the compounding of small failures into systemic instability.
We use COPQ as a unifying lens to prioritize action and measure improvement—aligning operators and executives around measurable financial impact.
What Makes GMPKit Different
Structural COPQ Diagnosis
We identify where execution friction is generating the largest financial loss—ensuring recovery effort is directed at the highest-impact constraints first.
Implementation Ownership
We lead implementation with site leadership. We do not deliver recommendations and exit. We assume responsibility for measurable outcomes.
Governance Discipline
Operational stability is not an outcome—it is a governance discipline. We build systems that prevent regression after the engagement ends.
Deep Pharmaceutical Operations Expertise
Our team brings direct operational experience across batch operations, inspection response, scale-up execution, and governance systems in GMP-regulated environments.
Global Experience. Local Execution.
Our team has delivered results across North America, Europe, and Asia—applying proven operational discipline directly alongside site leadership inside GMP-regulated manufacturing environments.
Our Commitment
When we engage, we align with site leadership to reduce Cost of Poor Quality and restore execution stability. Results are measured, governance is strengthened, and gains are protected.
Ready to Reduce COPQ?
Schedule a diagnostic call to discuss where execution friction may be generating financial loss in your operations.